Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On January 10, 2018, Accelerate Diagnostics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing certain preliminary financial results for the quarter ending December 31, 2017. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.
In accordance with General Instruction B.2 for Form 8-K, the information in this Item 2.02, including the related information contained in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
In addition to the disclosure described above under Item 2.02 of this Current Report on Form 8-K, the Press Release also announced the Company’s declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of its latest assay for the Accelerate Pheno™ system targeting severe bacterial pneumonia infections. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.The following materials are filed as exhibits to this Current Report on Form 8-K:
| Exhibit | |
| Number | Description |
| 99.1 | Press Release, dated January 10, 2018 |
Accelerate Diagnostics, Inc ExhibitEX-99.1 2 tv483117_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay,…To view the full exhibit click here
About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.
